文献速递炎症性肠病

抗TNF经治溃疡性结肠炎二线治疗:乌司奴单抗与JAK抑制剂优于维得利珠单抗

Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-Line Therapy in Anti-Tumor Necrosis Factor-Experienced Patients With Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-01-29

这项欧洲多中心回顾性研究纳入596例抗TNF-α经治后启动二线治疗的溃疡性结肠炎患者,比较维得利珠单抗、乌司奴单抗与JAK抑制剂的真实世界有效性和安全性。结果显示乌司奴单抗和JAK抑制剂在12个月无激素临床缓解和生化缓解上均优于维得利珠单抗,但JAK抑制剂不良事件发生率约高4倍。

要点

  • 乌司奴单抗和JAK抑制剂12个月无激素临床缓解优于维得利珠单抗。
  • 两者生化缓解同样优于维得利珠单抗,且彼此间无差异。
  • JAK抑制剂不良事件发生率约高4倍,需谨慎选择患者。

核心结论

  • 抗TNF-α失败后,乌司奴单抗和JAK抑制剂在诱导无激素及生化缓解方面优于维得利珠单抗。
  • JAK抑制剂的安全性担忧需要在临床实践中仔细选择患者。

研究设计与样本

  • 回顾性、多中心欧洲研究,纳入596例抗TNF-α经治后启动二线维得利珠单抗、乌司奴单抗或JAK抑制剂的成人溃疡性结肠炎患者。
  • 采用能量平衡权重(EBW)处理基线混杂,使用EBW加权Royston-Parmar生存模型分析12个月无激素临床缓解和生化缓解,并计算调整时间平均风险比(aHR)。
  • 不良事件率比较采用EBW加权Poisson回归。

主要发现

  • 共596例患者(维得利珠单抗301例、乌司奴单抗149例、JAK抑制剂146例),男性占54.7%,平均年龄43.9±15.5岁。
  • 与维得利珠单抗相比,乌司奴单抗和JAK抑制剂的12个月无激素临床缓解概率显著更高(aHR分别为1.54,95%CI 1.09-2.07;1.66,95%CI 1.07-2.53),两者间无差异。
  • 与维得利珠单抗相比,乌司奴单抗和JAK抑制剂的12个月生化缓解概率显著更高(aHR分别为2.26,95%CI 1.48-3.28;3.37,95%CI 2.01-5.36),两者间无差异。
  • JAK抑制剂不良事件发生率约为维得利珠单抗和乌司奴单抗的4倍,乌司奴单抗与维得利珠单抗之间无差异。
  • 英夫利西单抗是最常见的既往抗TNF-α药物(74.8%),继发性失效是主要停药原因(47.3%)。

临床怎么用

  • 对抗TNF-α失败的溃疡性结肠炎患者,二线可优先考虑乌司奴单抗或JAK抑制剂以提高缓解概率。
  • 使用JAK抑制剂前应评估安全性风险并仔细选择患者。

局限性

  • 回顾性研究设计可能残留混杂。
  • 真实世界数据,需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: With the advent of agents targeting distinct inflammatory pathways, therapeutic sequencing after anti-tumor necrosis factor alpha (TNF-α) failure in ulcerative colitis (UC) represents a major challenge. We compared the real-world effectiveness and safety of vedolizumab, ustekinumab, and Janus kinase inhibitors (JAKis) in anti-TNF-α-exposed patients. METHODS: In this retrospective, multicenter European study, adults with UC initiating second-line vedolizumab, ustekinumab, or a JAKi after anti-TNF-α were evaluated. Baseline confounding was addressed by applying energy balancing weights (EBWs). Effectiveness outcomes included probability of steroid-free clinical remission (SFCR) and biochemical SFCR at 12 months, analyzed using EBW-weighted Royston-Parmar survival models to derive adjusted time-averaged hazard ratios (aHRs). Adverse event (AE) rates were compared using EBW-weighted Poisson regression. RESULTS: A total of 596 patients were included (301 vedolizumab, 149 ustekinumab, 146 JAKi); 54.7% were male, with a mean age of 43.9 ± 15.5 years. Clinical activity, endoscopic scores, and biomarker levels were broadly comparable across treatment groups. Infliximab was the most common prior anti-TNF-α (74.8%), and secondary failure was the predominant discontinuation reason (47.3%). Compared with vedolizumab, both ustekinumab and JAKi showed significantly higher probability of SFCR (aHR, 1.54; 95% confidence interval [CI], 1.09-2.07; and aHR, 1.66; 95% CI, 1.07-2.53, respectively) and biochemical SFCR (aHR, 2.26; 95% CI, 1.48-3.28 and 3.37; 95% CI, 2.01-5.36, respectively) at 12 months, with no differences between them. JAKi recipients experienced an approximately 4-fold higher incidence of AEs, compared with both vedolizumab and ustekinumab, with no differences between ustekinumab and vedolizumab. CONCLUSIONS: Ustekinumab and JAKi were more effective than vedolizumab in inducing steroid-free and biochemical remission following anti-TNF-α failure. Safety concerns with JAKi warrant careful patient selection in clinical practice. CLINICALTRIALS: gov, Number: NCT06691061.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Privitera G, Bezzio C, Figlioli G, et al. Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-Line Therapy in Anti-Tumor Necrosis Factor-Experienced Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2026. PMID: 41616901. doi:10.1016/j.cgh.2026.01.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。